Want to see AU:IMU full AI Analyst Report?
Top Page
Imugene
(Sydney:IMU)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.07
▼(-4.29% Downside)
Action:Reiterated
Date:08/29/26
The score is weighed down primarily by weak financial performance (persistent losses, zero/declining revenue, and heavy negative free cash flow with a weakening equity base), reinforced by bearish technicals (price below all key moving averages and negative MACD). Valuation provides limited support because the negative P/E reflects ongoing losses and there is no dividend yield data.
Positive Factors
Relatively Low Leverage
Modest debt reduces immediate solvency pressure and leaves more flexibility than a highly leveraged structure. However, this benefit is tempered by shrinking assets and equity, so it does not remove the company’s need for future funding.
Negative Factors
Persistent Losses and Zero Revenue
The absence of recurring product revenue and continuing sizable losses indicate that the business is not self-sustaining. Until a candidate is commercialized or monetized, operating costs will continue to depend heavily on external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Relatively Low Leverage
Modest debt reduces immediate solvency pressure and leaves more flexibility than a highly leveraged structure. However, this benefit is tempered by shrinking assets and equity, so it does not remove the company’s need for future funding.
Read all positive factors
Imugene (IMU) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$36.25M
Dividend YieldN/A
Average Volume (3M)2.14M
Price to Earnings (P/E)―
Beta (1Y)2.29
Revenue GrowthN/A
EPS Growth-2.15%
CountryAU
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding533,088,260
10 Day Avg. Volume2,182,088
30 Day Avg. Volume2,137,260
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Imugene Business Overview & Revenue Model
Company Description
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogenei...
How the Company Makes Money
Imugene does not have widely disclosed, consistent product-revenue streams from marketed therapies; as a clinical-stage biotechnology company, its operations have typically been funded primarily through external financing rather than recurring sal...
Imugene Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 4.40M | 4.97M | 11.78M | 12.97M |
| Gross Profit | -6.84M | 4.40M | 4.97M | 9.57M | 10.56M |
| EBITDA | -68.11M | -67.42M | -147.98M | -47.42M | -48.06M |
| Net Income | -105.34M | -69.02M | -149.68M | -37.91M | -37.87M |
Balance Sheet | |||||
| Total Assets | 23.03M | 83.59M | 151.40M | 197.06M | 147.61M |
| Cash, Cash Equivalents and Short-Term Investments | 2.63M | 21.94M | 94.54M | 153.15M | 99.89M |
| Total Debt | 6.30M | 10.65M | 2.19M | 553.47K | 673.43K |
| Total Liabilities | 14.02M | 38.56M | 33.14M | 7.44M | 8.90M |
| Stockholders Equity | 9.01M | 45.03M | 118.25M | 189.63M | 138.70M |
Cash Flow | |||||
| Free Cash Flow | -44.85M | -90.03M | -108.80M | -29.78M | -30.93M |
| Operating Cash Flow | -44.85M | -75.57M | -101.73M | -29.78M | -30.67M |
| Investing Cash Flow | -4.35M | -12.70M | -7.25M | 9.63K | -414.16K |
| Financing Cash Flow | 29.99M | 17.37M | 49.43M | 82.98M | 101.35M |
Imugene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$5.33B | 119.03 | 7.11% | ― | 26.66% | 179.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$24.89M | -5.23 | 186.62% | ― | ― | 8.98% | |
45 Neutral | AU$72.21M | -0.89 | -98.86% | ― | ― | -27.73% | |
45 Neutral | AU$71.50M | -9.86 | -44.93% | ― | ― | 25.27% | |
45 Neutral | AU$846.89M | -7.97 | -51.15% | ― | ― | -44.83% | |
42 Neutral | AU$36.25M | -0.21 | -414.10% | ― | ― | -2.15% |
* Healthcare Sector Average
AU:IMU
Imugene
0.07
-0.20
-74.44%
AU:IMM
Immutep Ltd
0.05
-0.19
-79.57%
AU:PTX
Prescient Therapeutics Limited
0.07
0.03
70.00%
AU:TLX
Telix Pharmaceuticals
16.47
2.67
19.35%
AU:NOX
Noxopharm Ltd.
0.08
-0.03
-27.62%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.28
-0.89
-28.08%
Imugene Corporate Events
Imugene Posts Wider Loss and Sharp Fall in Net Tangible Assets
Aug 28, 2026
Imugene Limited reported audited results for the year ended 30 June 2026 showing no dividends declared or paid, consistent with the previous financial year. The company also confirmed there were no changes in controlled entities, no associates or ...
Imugene Restructures Convertible Notes and Raises Capital to Back Cancer Trials
Aug 27, 2026
Imugene has entered into an amended subscription agreement with an affiliate of Heights Capital Management, linked to Susquehanna International Group, to issue new convertible notes and warrants. The transaction restructures $2.1 million of existi...
Imugene Issues New Warrants and Convertible Notes to Bolster Funding
Aug 26, 2026
Imugene Limited has notified the market of the issue of new unquoted securities, including 25,301,205 warrants expiring in August 2031 and 4,200 convertible notes expiring in January 2030, both dated 21 August 2026. The move indicates the company ...
Imugene Cancels 4,200 Convertible Notes Under Capital Management Move
Aug 26, 2026
Imugene Limited has reported the cessation of 4,200 convertible notes, identified under ASX security code IMUAAR. The notes were cancelled by mutual agreement between the company and the holder, effective 21 August 2026.The cancellation slightly r...
Imugene Seeks ASX Quotation for 27.6 Million New Shares
Aug 26, 2026
Imugene Limited has applied for quotation of 27,578,949 ordinary fully paid shares on the ASX, with an issue date of August 25, 2026. The new securities are tied to previously announced transactions, indicating a follow-through on capital-raising ...
Imugene Restructures Convertible Notes to Boost Financial Flexibility
Aug 21, 2026
Imugene Limited has renegotiated the terms of its existing convertible notes with CVI Investments, Inc., redeeming A$2.1 million of the notes and replacing them with new senior, unsecured, zero-coupon convertible notes. The remaining existing note...
Imugene shareholders back capital-raising resolutions at extraordinary meeting
Aug 19, 2026
Imugene Limited has confirmed that all resolutions put to shareholders at its Extraordinary General Meeting on 19 August 2026 in Sydney were passed by poll. The approved resolutions include ratifying a prior tranche of placement shares and authori...
Imugene doubles down on azer-cel as leadership shifts and fresh capital backs trial push
Aug 9, 2026
Imugene has reaffirmed its strategic focus on advancing its lead CAR T candidate azer-cel through clinical development, despite a recent leadership change that saw long-serving chief executive Leslie Chong step down for personal reasons. During th...
Imugene’s Deep Out-of-the-Money Options Set to Expire Without Underwriting
Aug 5, 2026
Imugene has notified investors that 21,698,915 listed options trading under ASX code IMUOE, each exercisable at $4.012, will expire unexercised if not paid by 5pm AEST on 31 August 2026. Official quotation of these options will cease on 25 August ...
Imugene Discloses Final Director Interest as Leslie Chong Exits Board
Jul 31, 2026
Imugene Limited has notified the ASX that chief executive and managing director Leslie Chong ceased to be a director on 27 July 2026, triggering a formal disclosure of her final interests in the company’s securities. The filing details Chong...
Imugene Adjusts Capital Structure as Performance Rights Lapse
Jul 31, 2026
Imugene Limited has disclosed the lapse of 847,722 performance rights awards, recorded under ASX code IMUAAO, after the conditions attached to these rights were not met or became incapable of being satisfied. The cessation was effective on 27 July...
Imugene Advances Azer-cel Program and Bolsters Balance Sheet With Fresh Capital
Jul 30, 2026
Imugene reported strong clinical progress for its lead cell therapy, azer-cel, during the June quarter, including complete and partial responses in a Phase 1b cohort combining the CAR-T with BTK inhibitors, a drug class with global sales above US$...
Imugene posts third response in BTKi combo arm of azer-cel Phase 1b trial
Jul 27, 2026
Imugene has reported a third patient response in the concurrent Bruton Tyrosine Kinase inhibitor cohort of its Phase 1b azer-cel trial, including a partial response in a second Follicular Lymphoma patient who had previously progressed on BTKi ther...
Imugene CEO Leslie Chong Resigns After 11 Years, Leadership Search Begins
Jul 27, 2026
Imugene has announced that Managing Director and Chief Executive Officer Leslie Chong has resigned effective immediately for personal reasons after nearly 11 years with the company. The board has initiated a search for new leadership, with the sen...
Imugene Seeks ASX Quotation for 73.7 Million New Shares
Jul 13, 2026
Imugene Limited has applied for the quotation of 73,684,215 new ordinary fully paid shares on the Australian Securities Exchange. The application, lodged as a new announcement on July 13, 2026, formalises the move to have these securities traded u...
Imugene Seeks ASX Quotation for Additional Ordinary Shares
Jul 9, 2026
Imugene Limited has lodged a new Appendix 2A application with the ASX for the quotation of additional ordinary fully paid shares under its IMU ticker. The filing covers the issuance of 189,219 shares dated July 7, 2026, and a further 11,361 shares...
Imugene Trims Potential Dilution as Multiple Securities Expire and Lapse
Jul 7, 2026
Imugene Limited has notified the market of the cessation of several classes of securities, including convertible notes, options and restricted stock units, following cancellations, lapses of conditions and expiries without exercise. The changes, d...
Imugene Updates Director Equity Holdings for Jakob Dupont
Jul 7, 2026
Imugene has reported a change in the holdings of director Jakob Dupont, reflecting movements among his ordinary shares, employee options and restricted stock units. The update, lodged under ASX listing rules, shows new ordinary shares issued at ni...
Imugene outlines non-underwritten share placement and extensive offer disclaimers
Jul 7, 2026
Imugene Limited has released a capital raising presentation outlining a two-tranche, non-underwritten placement of new fully paid ordinary shares to investors. The offer is structured under Australian law and explicitly excludes any offer or sale ...
Imugene Plans Major ASX Share Placement to Boost Capital Base
Jul 7, 2026
Imugene Limited has notified the ASX of a proposed placement or other type of share issue, seeking approval for the quotation of new ordinary fully paid shares. The filing outlines the company’s intention to issue up to 117,052,638 IMU share...
Imugene Raises $11.1m to Fund Azer-cel After Strong Early Trial Data
Jul 7, 2026
Imugene has secured firm commitments to raise about $11.12 million via a discounted placement of roughly 117.1 million new shares to sophisticated, professional and institutional investors, including a global commercial-stage biopharmaceutical com...
Imugene Appoints New Director With No Declared Security Interests
Jul 6, 2026
Imugene Limited has disclosed changes in its boardroom, underscoring its status as a regulated, ASX-listed company that must formally record directors’ interests in accordance with Australian corporate law and market rules. The filing reinfo...
Imugene Requests ASX Trading Halt Ahead of Proposed Capital Raising
Jul 2, 2026
Imugene Limited has requested an immediate trading halt of its securities on the ASX, with the halt to remain in place until either an upcoming announcement is released or normal trading resumes on Tuesday, 7 July 2026. The company says the halt i...
Imugene’s azer-cel shows complete response in BTKi-refractory mantle cell lymphoma
Jul 1, 2026
Imugene reported new data from its Phase 1b basket trial of azer-cel, an allogeneic CD19-targeting CAR T therapy, showing a complete response in the first Mantle Cell Lymphoma patient treated in a concurrent Bruton Tyrosine Kinase inhibitor cohort...
Imugene’s azer-cel trial logs first complete response in BTKi-resistant lymphoma
Jun 30, 2026
Imugene has reported the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor cohort of its Phase 1b trial for azer-cel, an allogeneic CD19-targeting CAR T therapy for blood cancers. The response was seen at Day 28 in a folli...
Imugene Wins FDA Fast Track for Off-the-Shelf CAR T in CLL/SLL and MZL
Jun 9, 2026
Imugene has secured U.S. FDA Fast Track Designation for its off-the-shelf CD19-directed CAR T therapy azer-cel in two blood cancer indications, relapsed or refractory CLL/SLL and MZL. The status enables more frequent FDA engagement, rolling review...
Imugene Grants New Unquoted Equity Awards Under Employee Incentive Plan
Jun 2, 2026
Imugene Limited has issued 6,398,773 restricted stock units and 1,676,453 performance rights awards under its employee incentive scheme, with an issue date of 27 May 2026. The unquoted equity awards, which are not intended to be listed on the ASX,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.